US FDA gives final approval to Glenmark Pharma’s Sodium Phenylbutyrate tablets 

The US Food and Drug Administration (FDA) has given final approval to Glenmark Pharma’s Sodium Phenylbutyrate tablets USP, 500 mg, the generic version of Buphenyl Tablets, 500 mg, of Horizon Therapeutics, according to a statement from Glenmark Pharma.

The statement said that the tablets will be distributed in the US by Glenmark Pharma Inc., USA.